NanoViricides Inc (NYSEAMERICAN:NNVC) was the target of a significant drop in short interest in March. As of March 13th, there was short interest totalling 470,300 shares, a drop of 36.2% from the February 27th total of 737,500 shares. Currently, 7.5% of the company’s stock are sold short. Based on an average daily trading volume, of 4,050,000 shares, the days-to-cover ratio is presently 0.1 days.
Shares of NNVC stock traded up $0.77 during trading hours on Thursday, reaching $5.57. The company had a trading volume of 693,150 shares, compared to its average volume of 4,652,478. NanoViricides has a twelve month low of $1.27 and a twelve month high of $19.20.
A hedge fund recently raised its stake in NanoViricides stock. Renaissance Technologies LLC increased its stake in NanoViricides Inc (NYSEAMERICAN:NNVC) by 51.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 87,689 shares of the company’s stock after buying an additional 29,848 shares during the quarter. Renaissance Technologies LLC owned about 1.30% of NanoViricides worth $220,000 as of its most recent filing with the SEC.
NanoViricides, Inc, a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as injectable and oral anti-influenza nanoviricide drug for H7N9, Bird Flu H5N1, other Highly Pathogenic Influenzas, Epidemic Influenzas, and Seasonal Influenzas; DengueCide, an anti-dengue nanoviricide which is in pre-clinical development; and HIVCide, an anti-human immunodeficiency virus drug candidate.
Further Reading: 52 Week Highs
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.